신체증상을 호소하는 환자의 약물치료 = Pharmacotherapy for Patients Complaining With Somatic Symptoms

다국어 초록 (Multilingual Abstract)

Patients complaining with somatic symptoms are very common in clinical practice, and are often consulted to medical department. But it is difficult to treat well. The treatment of somatic symptom disorder is multi-modal as none of the methods on their own provide a satisfactory outcome. The treatment of somatic symptoms disorders is complicated by lack of boundary, conceptual clarity, and overemphasis on psychosocial causation and effectiveness of psychological treatments. In clinical practice all classes of psychotropics are used to treat somatic symptoms disorder. Drugs such as tricyclic antidepressants, serotonin reuptake inibitors(SSRI), serotonin and noradrenalin reuptake inhibitors (SNRI), atypical antipsychotics are studied. The evidence indicates that these drugs are effective in somatic symptom disorders. All classes of antidepressants seem to be effective against somatic symptom disorders. SSRIs are more effective against hypochondriasis and body dysmorphic disorder, and SNRIs appear to be more effective than other antidepressants when pain is predominant. The author suggest that psychiatrists should know how to treat patients complaining with somatic symptoms by using not only psychotherapeutic approach but also pharmacological treatment. It will be helpful to reduce suffering and increase quality of life of these patients.

국문 초록 (Abstract)

신체증상장애를 포함하여 다양하게 신체증상을 호소하는 환자는 여러 영역의 임상현장에서 자주 접할 수 있는 정신질환이지만 분류 및 개념이 명확하지 않음으로써 정확한 진단과 치료가 이뤄지지 못하는 경우가 많다.
치료는 환자에게서 원인을 찾거나 정신사회적 원인을 강조하면서 지나치게 인지행동치료를 포함한 정신치료에만 초점을 맞추기보다는 환자의 고통을 줄일 수 있는 대증요법을 시행하여야 한다. 정신사회적 원인론에 대한과도한 강조는 신체증상장애 환자들에게 도움이 되지 않을 뿐만이 아니라 이 질환의 약물치료에 대한 이해 및연구를 더욱 어렵게 할 뿐이다. 신체증상장애의 약물치료에 관한 연구는 개념과 경계의 불명확성, 그리고 기능성 신체증후군과의 중첩 등으로 인해 제대로 된 연구가 어렵다. 몇몇 체계적 연구들의 결과를 살펴보면 정신약물은 단기간에서는 효과적인 것으로 나타났다. 대부분의 항우울제가 신체증상을 호소하는 환자들에게 효과가있으며, 선택적 세로토닌 재흡수 차단제는 신체추형장애 및 건강염려증에서 그리고 세로토닌 노르아드레날린재흡수 차단제는 통증이 주된 증상인 환자들에게서 다른 항우울제보다 더 효과적이다. 정신건강의학과 의사들은 신체증상을 호소하는 환자들에게 적용할 수 있는 인지행동치료를 포함한 다양한 정신치료적 기법뿐만이 아니라 약물치료에서 정신약물 및 비정신약물의 사용을 잘 알고 사용함으로써 이 환자들을 도울 수 있을 것이다.

참고문헌 (Reference)

1 이경규, "신체증상을 호소하는 환자의 정신치료" 한국정신분석학회 24 (24): 78-85, 2013

2 Johansen ML, "What is the problem with medically unexplained symptoms for GPs? A meta-synthesis of qualitative studies" 100 : 647-654, 2017

3 Sumathipala A, "What is the evidence for the efficacy of treatment for somatoform disorder? A critical review of previous intervention studies" 69 : 889-900, 2007

4 Han C, "Venlafaxine versus mirtazapine in the treatment of undifferentiated somatoform disorder : a 12 week prospective, open-label, randomized, parallel-group trial" 28 : 251-261, 2008

5 Schreiber S, "Venlafaxine and mirtazapine : Different mechanisms of antidepressant action, common opioid-mediated antinociceptive effects-A possible opioid involvement in severe depression" 18 : 143-149, 2002

6 Muller T, "Treatment of somatoform disorders with St John’s wort : a randomized double-blind and placebo-controlled trial" 66 : 538-547, 2004

7 Garcia-Campayo J, "Topiramate as a treatment for pain in multisomatoform disorder patients : an open trial" 24 : 417-421, 2002

8 Mula M, "The role of anticonvulsant drugs in anxiety disorders : a critical review of the evidence" 27 : 263-272, 2007

9 Pilowsky L, "The response to treatment in hypochondriacal disorders" 2 : 88-92, 1968

10 Fallon BA, "The pharmacotherapy of hypochondriasis" 32 : 607-611, 1996

11 Bass C, "The management of chronic somatisation" 162 : 472-480, 1993

12 World Health Organization, "The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines"

13 Delargy MA, "Successful rehabilitation in conversion paralysis" 292 : 1730-1731, 1986

14 Bass C, "Somatoform disorder : Severe psychiatric illnesses neglected by psychiatrists" 179 : 11-14, 2001

15 Noyes R Jr, "Somatization. Diagnosis and management" 4 : 790-795, 1995

16 Barsky AJ, "Somatization increases medical utilization and costs independent of psychiatric and medical comorbidity" 62 : 903-910, 2005

17 Chaturvedi SK, "Somatic symptoms in a community clinic" 30 : 369-374, 1988

18 Sussman N, "SNRIs versus SSRIs : mechanisms of action in treating depressions and painful physical symptoms" 5 : 19-26, 2003

19 Fink P, "Recent developments in the understanding and management of functional somatic symptoms in primary care" 21 : 182-188, 2008

20 Somashekar B, "Psychopharmacotherapy of somatic symptoms disorder" 25 : 107-115, 2013

21 Jeffery LJ, "Prevalence, impact and prognosis of multisomatoform disorder in primary care : a 5-year follow-up study" 70 : 430-434, 2008

22 Harnack D, "Pregabalin in patients with antidepressant treatment-resistant Somatoform disorders-a case series" 27 : 537-539, 2007

23 Fallon BA, "Pharmacotherapy of somatoform disorders" 56 : 455-460, 2004

24 Kleinstäuber M, "Pharmacological interventions for somatoform disorders in adults" 7-, 2013

25 Kroenke K, "Patients presenting with somatic complaints : epidemiology, psychiatric co-morbidity and management" 12 : 34-43, 2003

26 Henningsen P, "Management of somatic symptom disorder" 20 : 23-31, 2018

27 Altamura AC, "Levosulpiride in somatoform disorders : a double blind placebo-controlled cross-over study" 7 : 155-159, 2003

28 Volz HP, "John’s wort extract(LI160)in somatoform disorders : results of a placebo-controlled trial" 164 : 294-300, 2002

29 Wesner RB, "Imipramine : an effective treatment for illness phobia" 22 : 43-48, 1991

30 Chesler EJ, "Genotype-dependence of gabapentin and pregabalin sensitivity : the pharmacogenetic mediation of analgesia is specific to the type of pain being inhibited" 106 : 325-335, 2003

31 Garcia-Campayo J, "Gabapentin for the treatment of patients with somatization disorder" 62 : 474-, 2001

32 Guglielmo R, "Gabapentin as Add-On Treatment for Somatoform Disorder : a Case Report" 35 : 45-46, 2012

33 Wessely S, "Functional somatic syndromes : one or many" 354 : 936-939, 1999

34 Perugi G, "Fluvoxamine in the treatment of body dysmorphic disorder(dysmorphophobia)" 11 : 247-254, 1996

35 Noyes R Jr, "Fluvoxamine for somatoform disorders : an open trial" 20 : 339-344, 1998

36 Han C, "Fluoxetine versus sertraline in the treatment of patients with undifferentiated somatoform disorder : a randomized, open-label, 12-week, parallel-group trial" 32 : 437-444, 2008

37 Fallon BA, "Fluoxetine for hypochondriacal patients without major depression" 13 : 438-441, 1993

38 Muller JE, "Escitalopram in the treatment of multisomatoform disorder : A double-blind placebo-controlled trail" 23 : 43-48, 2008

39 Magarinos M, "Epidemiology and treatment of hypochondriasis" 16 : 9-22, 2002

40 Kroenke K, "Efficacy of treatment for somatoform disorders : a review of randomized controlled trials" 69 : 881-888, 2007

41 Phillips KA, "Efficacy and safety of fluvoxamine in body dysmorphic disorder" 59 : 165-171, 1998

42 Phillips KA, "Effectiveness of pharmacotherapy for body dysmorphic disorder : a chart-review study" 62 : 721-727, 2001

43 Nagoshi Y, "Effect of aripiprazole augmentation for treatment-resistant somatoform disorder : a case series" 34 : 397-398, 2014

44 Fishbain DA, "Do antidepressants have an analgesic effect in psychogenic pain and somatoform pain disorder? A meta-analysis" 60 : 503-509, 1998

45 American Psychiatric Association, "Diagnostic and Statistical Manual of Mental Disorders" American Psychiatric Publishing 2000

46 American Psychiatric Association, "Diagnostic and Statistical Manual of Mental Disorders" American Psychiatric Publishing 2013

47 Kroenke K, "Common symptoms in ambulatory care : Incidence, evaluation, therapy and outcome" 86 : 262-266, 1989

48 Greeven A, "Cognitive behavior therapy and paroxetine in the treatment of hypochondriasis : a randomized controlled trial" 164 : 91-99, 2007

49 Hollander E, "Clomipramine vs desipramine crossover trail in body dysmorphic disorder : Selective efficacy of a serotonin reuptake inhibitor in imagined ugliness" 56 : 1033-1039, 1999

50 Nagoshi Y, "Blonanserin augmentation for treatment-resistant somatic symptom disorder : a case series" 39 : 112-114, 2016

51 Speed J, "Behavioral management of conversion disorder : retrospective study" 77 : 147-154, 1996

52 Lynch ME, "Antidepressants as analgesics : a review of randomized controlled trials" 26 : 30-36, 2001

53 O’Malley PG, "Antidepressant therapy for unexplained medical symptoms and syndromes" 48 : 980-990, 1999

54 Stahl SM, "Anticonvulsants as anxiolytics, part 2 : pregabalin and gabapentin as alpha(2)delta ligands at voltage-gated calcium channels" 65 : 460-461, 2004

55 Phillips KA, "An open label study of citalopram in body dysmorphic disorder" 64 : 715-720, 2003

56 Trieschmann RB, "An approach to the treatment of abnormal ambulation resulting from conversion reaction" 51 : 198-206, 1970

57 Phillips KA, "A randomized placebo-controlled trial of fluoxetine in body dysmorphic disorder" 59 : 381-388, 2002

58 Luo Y, "A randomized double-blind clinical trial on analgesic efficacy of fluoxetine for persistent somatoform pain disorder" 33 : 1522-1525, 2009

59 Fallon BA, "A doublemasked, placebo-controlled study of fluoxetine for hypochondriasis" 28 : 638-645, 2008